Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer

The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma.Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases.Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients’ quality of life.

Download Full-text

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

Journal of Clinical Oncology ◽

10.1200/jco.2017.75.2170 ◽

2018 ◽

Vol 36 (8) ◽

pp. 757-764 ◽

Cited By ~ 15

Author(s):

David Cella ◽

Bernard Escudier ◽

Nizar M. Tannir ◽

Thomas Powles ◽

Frede Donskov ◽

...

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Bone Metastases ◽

Cell Carcinoma ◽

Renal Cell ◽

Repeated Measures ◽

Objective Response ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma

Purpose In the phase III METEOR trial ( ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and objective response rate compared with everolimus. Changes in quality of life (QoL), an exploratory end point, are reported here. Patients and Methods Patients completed the 19-item Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI-19) and the five-level EuroQol (EQ-5D-5L) questionnaires at baseline and throughout the study. The nine-item FKSI–Disease-Related Symptoms (FKSI-DRS), a subset of FKSI-19, was also investigated. Data were summarized descriptively and by repeated-measures analysis (for which a clinically relevant difference was an effect size ≥ 0.3). Time to deterioration (TTD) was defined as the earlier of date of death, radiographic progressive disease, or ≥ 4-point decrease from baseline in FKSI-DRS. Results The QoL questionnaire completion rates remained ≥ 75% through week 48 in each arm. There was no difference over time for FKSI-19 Total, FKSI-DRS, or EQ-5D data between the cabozantinib and everolimus arms. Among the individual FKSI-19 items, cabozantinib was associated with worse diarrhea and nausea; everolimus was associated with worse shortness of breath. These differences are consistent with the adverse event profile of each drug. Cabozantinib improved TTD overall, with a marked improvement in patients with bone metastases at baseline. Conclusion In patients with advanced renal cell carcinoma, relative to everolimus, cabozantinib generally maintained QoL to a similar extent. Compared with everolimus, cabozantinib extended TTD overall and markedly improved TTD in patients with bone metastases.

Download Full-text

MP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMA

The Journal of Urology ◽

10.1016/j.juro.2015.02.2512 ◽

2015 ◽

Vol 193 (4S) ◽

Author(s):

Yong Han ◽

Ashley Wietsma ◽

Cary Gross ◽

Nilay Shah ◽

Robert Abouassaly ◽

...

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Renal Cell Carcinoma ◽

Overall Survival ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Complete Response

Download Full-text

27 Quality of life in metastatic renal cell carcinoma patients with ECOG PS >2 receiving targeted therapy

Critical Reviews in Oncology/Hematology ◽

10.1016/s1040-8428(11)70046-4 ◽

2011 ◽

Vol 78 ◽

pp. S22

Author(s):

I. Tsimafeyeu

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Ecog Ps

Download Full-text

Bone metastases from renal cell carcinoma: A case report and literature review

Journal of Clinical Images and Medical Case Reports ◽

10.52768/2766-7820/1426 ◽

2021 ◽

Vol 2 (6) ◽

Author(s):

Mouadh Nefiss ◽

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Bone Metastases ◽

Cell Carcinoma ◽

Renal Cell ◽

Oncologic Outcomes ◽

Surgical Decision ◽

Patient Profile ◽

Risk Balance

Management of bone metastases from Renal Cell Carcinoma (RCC) has significantly changed after the era of targeted therapy that improved the overall survival. This has sucked the different interveners in their management to push the surgical indications in order to improve outcome and quality of life for these patients. In case of a solitary metastasis or a limited number of resectable metastases wide resections have to be considered according to patient profile, comorbidities, localization, heaviness of the surgery and to benefit –risk balance. However such surgeries are highly demanding procedures that must be carefully planned and discussed in multidisciplinary team and with patient. Thus, surgical decision-making for a second metastasis and according to what criteria remains a subject of controversy. We report a case of an aggressive metastatic renal cell carcinoma with good functional and oncologic outcomes 3 years after surgery coupled with anti-angiogenic treatment. A review of the literature concerning recent attitudes in the management of bony metastatic renal carcinoma was carried out. Keywords: renal cell carcinoma; bone metastases; surgery; targeted therapy.

Download Full-text

Some characteristics of the treatment of generalized and disseminated renal cell carcinoma

Bulletin of Siberian Medicine ◽

10.20538/1682-0363-2004-2-66-73 ◽

2004 ◽

Vol 3 (2) ◽

pp. 66-73

Author(s):

O. V. Leonov ◽

V. T. Dolgikh ◽

V. I. Shirocorad ◽

Ye. I. Kopyltsov ◽

D. V. Dolgikh

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Surgical Treatment ◽

Cell Carcinoma ◽

Surgical Approach ◽

Postoperative Period ◽

Renal Cell ◽

Treatment Results ◽

Combined Surgery

In the article 206 treatment results of generalized and disseminated renal cell carcinoma are presented. It has been found that disseminated forms of hypernephroma required a combined surgical treatment without fail; nephrectomy added by adrenalectomy is recommended insuperpolar tumour localization. Combined surgery with resection or ablation of the affected organ seems to be advisable in disseminated renal cell carcinoma. Such an active surgical approach improves the prognosis. Medicamental antineoplastic therapy including immunotherapy in postoperative period can raise patients survivability and quality of life.

Download Full-text